Figure 3
Evaluation of the antiviral effects of shRNA-2B on survival rate. BALB/c mice (n = 10) were injected with plasmid (40 μg/mouse) or lentivirus (1 × 108 TU/mouse) through a tail vein, 24 h, post injection, 8 × 103 pfu/mouse of CVB3 was used as the challenge.